thalidomide has been researched along with Immune System Diseases in 6 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Immune System Diseases: Disorders caused by abnormal or absent immunologic mechanisms, whether humoral, cell-mediated, or both.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Thalidomide was withdrawn from the market in the early sixties because of its teratogenic effects." | 2.41 | [Thalidomide: new uses for an old drug]. ( Sonneveld, P; Wu, KL, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (50.00) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gentile, M | 1 |
| Recchia, AG | 1 |
| Vigna, E | 1 |
| Mazzone, C | 1 |
| Lucia, E | 1 |
| Gigliotti, V | 1 |
| Bossio, S | 1 |
| Madeo, A | 1 |
| Morabito, L | 1 |
| Servillo, P | 1 |
| Franzese, S | 1 |
| Caruso, N | 1 |
| De Stefano, L | 1 |
| Bisconte, MG | 1 |
| Gentile, C | 1 |
| Morabito, F | 1 |
| Wu, KL | 1 |
| Sonneveld, P | 1 |
| Schuler, U | 1 |
| Ehninger, G | 1 |
| Vaisman, B | 1 |
| Keravich, DP | 1 |
| Daniels, CE | 1 |
| Drenth, JP | 1 |
| Vonk, AG | 1 |
| Simon, A | 1 |
| Powell, R | 1 |
| van der Meer, JW | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Pilot Trial of Topical Thalidomide for the Management of Chronic Discoid Lupus Erythematosus[NCT00001680] | Phase 2 | 17 participants | Interventional | 1997-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for thalidomide and Immune System Diseases
| Article | Year |
|---|---|
Lenalidomide in the treatment of chronic lymphocytic leukemia.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Combined Modality Therapy; Humans; Immune System Di | 2011 |
[Thalidomide: new uses for an old drug].
Topics: Angiogenesis Inhibitors; Drug Approval; Erythema Nodosum; Graft vs Host Disease; Humans; Immune Syst | 2002 |
Thalidomide: rationale for renewed use in immunological disorders.
Topics: Bone Marrow Transplantation; Cell Adhesion Molecules; Female; HIV Infections; Humans; Immune System | 1995 |
Mechanism of teratogenic action of thalidomide.
Topics: Abnormalities, Drug-Induced; Animals; Ascorbic Acid; Extremities; Female; Humans; Immune System Dise | 1996 |
1 trial available for thalidomide and Immune System Diseases
| Article | Year |
|---|---|
Limited efficacy of thalidomide in the treatment of febrile attacks of the hyper-IgD and periodic fever syndrome: a randomized, double-blind, placebo-controlled trial.
Topics: Acute-Phase Reaction; Adult; Cross-Over Studies; Cytokines; DNA Mutational Analysis; Double-Blind Me | 2001 |
1 other study available for thalidomide and Immune System Diseases
| Article | Year |
|---|---|
Challenges of thalidomide distribution in a hospital setting.
Topics: Anti-Infective Agents; Drug Prescriptions; Erythema Nodosum; Female; Guidelines as Topic; Humans; Im | 1999 |